NAYA Biosciences Inc
NASDAQ:NAYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1.2), the stock would be worth $11.26 (412% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.2 | $2.2 |
0%
|
| 3-Year Average | 1.2 | $11.26 |
+412%
|
| 5-Year Average | 25 | $232.37 |
+10 462%
|
| Industry Average | 1.7 | $16.22 |
+637%
|
| Country Average | 2.4 | $22.64 |
+929%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$1.5m
|
/ |
Oct 2024
$6.2m
|
= |
|
|
$1.5m
|
/ |
Dec 2024
$6.5m
|
= |
|
|
$1.5m
|
/ |
Dec 2025
$7.1m
|
= |
|
|
$1.5m
|
/ |
Dec 2026
$7.8m
|
= |
|
|
$1.5m
|
/ |
Dec 2027
$66.9m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
1.5m USD | 0.2 | -0.2 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 16.2 | 57.2 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 3.5 | 24.9 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 4.6 | 35.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 2.9 | 22.4 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 4.1 | 23.8 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 7.8 | 44.7 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 1.7 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 10.5 | 42.8 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 1.9 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 5.5 | 19.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
